T1	p 304 332	patients with chronic immune
T2	p 452 482	adults with previously treated
T3	p 799 817	computer-generated
T4	p 972 980	status .
T5	p 1503 1517	Between Nov 22
T6	p 1531 1538	July 31
T7	p 1548 1565	197 patients were
T8	p 1753 1762	treatment
T9	p 2075 2083	patients
T10	p 2209 2217	patients
T11	p 2345 2375	patients receiving eltrombopag
T12	p 2479 2491	patients and
T13	p 2605 2624	eltrombopag-treated
T14	p 2731 2738	placebo
T15	p 2787 2788	(
T16	p 2965 2986	patients who have not
T17	p 3000 3023	splenectomy or previous
T18	i 6 17	Eltrombopag
T19	i 132 143	Eltrombopag
T20	i 150 186	oral thrombopoietin receptor agonist
T21	i 268 300	daily eltrombopag versus placebo
T22	i 424 442	placebo-controlled
T23	i 662 737	with local standard of care plus 50 mg eltrombopag or matching placebo once
T24	i 1358 1386	eltrombopag versus placebo .
T25	i 1678 1692	62 placebo ) .
T26	i 1838 1845	placebo
T27	i 1909 1920	eltrombopag
T28	i 1954 1961	placebo
T29	i 2094 2105	eltrombopag
T30	i 2175 2184	placebo (
T31	i 2309 2318	placebo (
T32	i 2436 2445	placebo .
T33	i 2511 2518	placebo
T34	i 2657 2666	placebo )
T35	i 2731 2738	placebo
T36	i 2818 2831	eltrombopag .
T37	i 2847 2858	Eltrombopag
T38	o 44 69	immune thrombocytopenia (
T39	o 333 349	thrombocytopenia
T40	o 490 506	thrombocytopenia
T41	o 531 539	duration
T42	o 557 578	platelet counts lower
T43	o 872 886	platelet count
T44	o 930 955	immune thrombocytopenia ,
T45	o 1115 1123	response
T46	o 1190 1204	platelet count
T47	o 1480 1493	NCT00370331 .
T48	o 2240 2253	needed rescue
T49	o 2380 2401	thromboembolic events
T50	o 2547 2587	alanine aminotransferase concentration ,
T51	o 2684 2701	total bilirubin .
T52	o 2743 2768	serious bleeding events ,
T53	o 2898 2921	immune thrombocytopenia
T54	o 3133 3142	. FUNDING